What is HC Wainwright’s Forecast for MIST Q3 Earnings?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Equities researchers at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of Milestone Pharmaceuticals in a research report issued on Wednesday, August 12th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.22) for the quarter, down from their previous estimate of ($0.19). The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.82) EPS, FY2029 earnings at $1.01 EPS and FY2030 earnings at $1.69 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $0.56 million during the quarter, compared to analyst estimates of $0.82 million.

Several other research analysts have also commented on MIST. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Wells Fargo & Company decreased their target price on Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Tuesday, July 14th. Finally, Zacks Research upgraded Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Milestone Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $7.25.

Milestone Pharmaceuticals Stock Performance

Milestone Pharmaceuticals stock opened at $1.07 on Friday. The company has a market cap of $133.22 million, a PE ratio of -1.55 and a beta of 0.98. Milestone Pharmaceuticals has a 12 month low of $1.00 and a 12 month high of $3.06. The company has a fifty day moving average price of $1.23 and a two-hundred day moving average price of $1.52. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.18 and a quick ratio of 9.09.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Strategic Family Wealth Counselors L.L.C. bought a new stake in shares of Milestone Pharmaceuticals during the 4th quarter worth about $25,000. Eaton Financial Holdings Company LLC bought a new position in shares of Milestone Pharmaceuticals in the fourth quarter valued at approximately $26,000. Bank of America Corp DE boosted its holdings in shares of Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after acquiring an additional 16,044 shares in the last quarter. Cetera Investment Advisers acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $42,000. Finally, Invesco Ltd. acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $44,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.